The New England journal of medicine, 2019-11, Vol.381 (22), p.2114-2124
2019
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
- Ist Teil von
- The New England journal of medicine, 2019-11, Vol.381 (22), p.2114-2124
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Relapse of neuromyelitis optica spectrum disorder occurred in 20% of patients who received satralizumab, a subcutaneous anti–interleukin-6 antibody, as compared with 43% of those in the placebo group. The drug may have been more effective in patients with anti–aquaporin-4 IgG antibody than in those without the antibody.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1901747Titel-ID: cdi_proquest_miscellaneous_2319500412
- Format
- –
- Schlagworte
- Adolescent, Adult, Aged, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Monoclonal, Humanized - therapeutic use, Antigens, Aquaporin 4, Aquaporin 4 - immunology, Autoantibodies, Autoantibodies - blood, Autoimmune diseases, Central nervous system, Cytokines, Design, Double-Blind Method, Drug dosages, Drug Therapy, Combination, Fatigue, Female, Humans, Immunoglobulin G, Immunoglobulin G - blood, Immunosuppressive Agents - therapeutic use, Interleukin 6, Male, Middle Aged, Monoclonal antibodies, Multiple sclerosis, Neuromyelitis, Neuromyelitis Optica - drug therapy, Neuromyelitis Optica - immunology, Pain, Pharmaceuticals, Receptors, Interleukin-6 - antagonists & inhibitors, Receptors, Interleukin-6 - immunology, Recurrence, Technical communication, Teenagers, Young Adult